« Zurück
Startseite /
Pyrrolidinedithiocarbamate (ammonium)

Pyrrolidinedithiocarbamate (ammonium)

ArtNr	HY-18738-50mg
Hersteller	MedChem Express
CAS-Nr.	5108-96-3
Menge	50 mg
Quantity options	100 mg 10 mM/1 mL 50 mg
Kategorie	Neuroscience Neuroinflammation Metabolism Diabetes Glucose Homeostasis Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	98.0
Citations	[1]Németh ZH, et al. Pyrrolidinedithiocarbamate inhibits NF-kappaB activation and IL-8 production in intestinal epithelial cells. Immunol Lett. 2003 Jan 2;85(1):41-6.\|[2]Qin JD, et al. Effect of ammonium pyrrolidine dithiocarbamate (PDTC) on NF-κB activation and CYP2E1 content of rats with immunological liver injury. Pharm Biol. 2014 Nov;52(11):1460-1466. Acta Pharm Sin B. 2022 Sep;12(9):3618-3638.\|Acta Pharm Sin B. 2024 Dec 31.\|Acta Pharmacol Sin. 2023 Feb 24.\|Acta Pharmacol Sin. 2025 Mar 20.\|Am J Cancer Res. 2023 Mar;13(2):419-435.\|Am J Transl Res. 2018 Dec 15;10(12):4247-4257.\|Andrology. 2022 Nov 10.\|Ann Hepatol. 2023 Dec 18:101279.\|Antivir Res. 2023 Feb 20;105559.\|Arch Biochem Biophys. 2020 Feb 15;680:108242.\|Biochim Biophys Acta Mol Basis Dis. 2023 Oct;1869(7):166819.\|Biomed Pharmacother. 2019 Dec;120:109527.\|BMC Microbiol. 2019 Jul 29;19(1):170.\|Brain Behav Immun Health. 29 October 2022, 100546.\|Brain Behav Immun. 2020 Nov;90:108-137.\|Brain Res Bull. 2021 Sep 10;S0361-9230(21)00268-9.\|Cancers (Basel). 2023 Mar 6;15(5):1624.\|Cell Death Dis. 2021 Jan 11;12(1):67.\|Cell Death Dis. 2019 Feb 8;10(2):113. \|Cell Rep Med. 2024 May 16:101580.\|Cell Rep Med. 2025 Jan 16:101922.\|Cell Signal. 2021 Aug 29;110137.\|Cell Signal. 2024 Sep 18:111427.\|Chem Biol Interact. 2022 Jul 30;110068.\|Clin Transl Med. 2022 Jun;12(6):e850.\|Cytokine. 2022 Nov 22;162:156086.\|Dev Cell. 2025 Feb 7:S1534-5807(25)00034-6.\|Diabetes. 2024 Jun 13:db230969.\|EBioMedicine. 2024 Sep 16:108:105344.\|EMBO Rep. 2021 Jul 5;22(7):e51678.\|Evid-Based Compl Alt. 2021 Apr 2.\|Exp Biol Med. 2023 Jan 23;15353702221147568.\|Exp Eye Res. 2021 Feb 17;108507.\|Eye Vis (Lond). 2022 Sep 5;9(1):35.\|FEBS Lett. 2021 Aug 13.\|Food Biosci. 2021, 101268.\|Front Cell Dev Biol. 2021 Feb 11;9:570451.\|Gut Microbes. 2024 Jan-Dec;16(1):2313769.\|Heliyon. 2023 Nov 20.\|Hum Cell. 2023 Aug 7.\|Inflammation. 2020 Jun;43(3):916-936. \|Inflammation. 2021 Mar 2.\|Int Immunopharmacol. 2020 Jan;78:106043.\|Int Immunopharmacol. 2021, 107779.\|Int Immunopharmacol. 2023 Jun 19;121:110433.\|Int Immunopharmacol. 2024 Sep 19;142(Pt B):113151.\|Int Immunopharmacol. 2019 Feb 18;70:28-36. \|Int J Biol Macromol. 2022 Oct 21;S0141-8130(22)02401-1.\|Int J Biol Sci. 2019 Jan 24;15(3):688-700.\|Int J Mol Sci. 2020 Dec 23;22(1):E60.\|Int J Mol Sci. 2021 Nov 11;22(22):12188.\|Int J Mol Sci. 2023 Jul 11, 24(14), 11331.\|Int J Oncol. 2020 Jan;56(1):101-112.\|Int J Pharm. 2022 Nov 1;122361.\|J Cell Physiol. 2019 Aug;234(10):18731-18747. \|J Cell Physiol. 2019 Dec;234(12):23302-23314. \|J Dairy Sci. 2022 Dec 6;S0022-0302(22)00707-X.\|J Dairy Sci. 2024 Jul 19:S0022-0302(24)01027-0.\|J Dairy Sci. 2024 Nov 25:S0022-0302(24)01331-6.\|J Ethnopharmacol. 2023 Apr 24;116533.\|J Exp Med. 2020 Jul 6;217(7):e20192083. \|J Headache Pain. 2024 Jan 5;25(1):3.\|J Inflamm Res. 2021 Mar 5;14:719-735.\|J Inflamm Res. 2021 Oct 5;14:5079-5094.\|J Nat Prod. 2021 Mar 16.\|J Neuroinflammation. 2021 Jun 28;18(1):146.\|J Periodontal Res. 2023 Oct 26.\|J Periodontol. 2024 Jun 27.\|JACC Basic Transl Sci. 2022 Aug 3;7(8):820-840.\|Lasers Med Sci. 2023 Oct 18;38(1):240.\|Liver Int. 2022 Oct 17.\|Mediat Inflamm. 2020 Jul 24;2020:8298615.\|Microbiome. 2023 Jan 31;11(1):17.\|Microorganisms. 2021 Sep 17;9(9):1983.\|Mil Med Res. 2023 Nov 25;10(1):56.\|Mol Immunol. 21 October 2022.\|Mol Med Rep. 2020 Nov;22(5):4227-4235.\|Mol Med. 2021 Dec 11;27(1):156.\|Mol Med. 2023 Aug 21;29(1):113.\|Mol Neurobiol. 2021 Apr 15.\|Mol Neurobiol. 2022 Sep 2.\|Nat Commun. 2024 Jan 10;15(1):449.\|Nat Commun. 2024 Sep 12;15(1):7996.\|Oncogene. 2022 Mar;41(13):1866-1881.\|Oncoimmunology. 2018 Aug 23;7(11):e1461303. \|Oncotarget. 2020 Feb;39(7):1414-1428.\|Oxid Med Cell Longev. 2017;2017:3869561.\|Oxid Med Cell Longev. 2021 Mar 30.\|Parasit Vectors. 2020 Aug 31;13(1):435.\|Pharmacol Res. 2018 Jul;133:218-235.\|Phytomedicine. September 2022, 154290.\|Phytother Res. 2023 Jul 11.\|PPAR Res. 26 Aug 2021.\|Redox Biol. 2021 Oct;46:102098.\|Research Square Preprint. 2021 Jan.\|Research Square Preprint. 2021 Jul.\|Research Square Preprint. 2023 Dec 1.\|Research Square Preprint. 2023 Jul 25.\|Research Square Preprint. July 21st, 2022.\|Research Square Print. 2022 Aug.\|Research Square Print. 2022 Jun.\|Research Square Print. December 14th, 2022.\|Sci Rep. 2024 Nov 4;14(1):26583.\|Sci Total Environ. 2024 Jul 30:949:175139.\|Sci Total Environ. 2024 May 10:933:173079.\|Signal Transduct Target Ther. 2023 Mar 15;8(1):107.\|SSRN. 2024 Jan 9.\|Theranostics. 2021 Jan 19;11(7):3392-3416.\|Vaccines. 2019 Dec 14;7(4):216.\|Vet Parasitol. 2022 May;305:109710.\|Vet Res. 2024 Jul 29;55(1):93.\|Vet Sci. 2024 May 8;11(5):204.\|Exp Neurol. 2024 Apr 27:377:114794.
Smiles	SC(N1CCCC1)=S.N
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Ammonium pyrrolidinedithiocarbamate,PDTC (ammonium),APDC
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	NF-κB
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	164.29
Product Description	Pyrrolidinedithiocarbamate ammonium (Ammonium pyrrolidinedithiocarbamate) is a selective and blood-brain barrier (BBB) permeable NF-κB inhibitor.
Manufacturer - Research Area	Inflammation/Immunology; Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic)\|H2O: 50 mg/mL (ultrasonic)
Manufacturer - Pathway	NF-κB
Isoform	NF-κB
Clinical information	Phase 3

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-18738-50mg-safety-datasheet.pdf